S&P 500   5,151.19 (-0.92%)
DOW   38,162.29 (-0.77%)
QQQ   440.35 (-1.13%)
AAPL   176.66 (+0.93%)
MSFT   423.89 (-0.94%)
META   516.81 (-1.21%)
GOOGL   158.50 (-0.57%)
AMZN   187.40 (-0.87%)
TSLA   172.43 (-1.24%)
NVDA   895.04 (-1.23%)
AMD   164.15 (-3.72%)
NIO   4.15 (-6.95%)
BABA   72.46 (-3.19%)
T   16.42 (+0.00%)
F   12.68 (-2.76%)
MU   123.64 (-3.04%)
GE   154.31 (-1.96%)
CGC   8.31 (+1.96%)
DIS   114.50 (-2.26%)
AMC   2.71 (-3.21%)
PFE   26.17 (-0.65%)
PYPL   65.17 (-0.96%)
XOM   122.04 (+0.21%)
S&P 500   5,151.19 (-0.92%)
DOW   38,162.29 (-0.77%)
QQQ   440.35 (-1.13%)
AAPL   176.66 (+0.93%)
MSFT   423.89 (-0.94%)
META   516.81 (-1.21%)
GOOGL   158.50 (-0.57%)
AMZN   187.40 (-0.87%)
TSLA   172.43 (-1.24%)
NVDA   895.04 (-1.23%)
AMD   164.15 (-3.72%)
NIO   4.15 (-6.95%)
BABA   72.46 (-3.19%)
T   16.42 (+0.00%)
F   12.68 (-2.76%)
MU   123.64 (-3.04%)
GE   154.31 (-1.96%)
CGC   8.31 (+1.96%)
DIS   114.50 (-2.26%)
AMC   2.71 (-3.21%)
PFE   26.17 (-0.65%)
PYPL   65.17 (-0.96%)
XOM   122.04 (+0.21%)
S&P 500   5,151.19 (-0.92%)
DOW   38,162.29 (-0.77%)
QQQ   440.35 (-1.13%)
AAPL   176.66 (+0.93%)
MSFT   423.89 (-0.94%)
META   516.81 (-1.21%)
GOOGL   158.50 (-0.57%)
AMZN   187.40 (-0.87%)
TSLA   172.43 (-1.24%)
NVDA   895.04 (-1.23%)
AMD   164.15 (-3.72%)
NIO   4.15 (-6.95%)
BABA   72.46 (-3.19%)
T   16.42 (+0.00%)
F   12.68 (-2.76%)
MU   123.64 (-3.04%)
GE   154.31 (-1.96%)
CGC   8.31 (+1.96%)
DIS   114.50 (-2.26%)
AMC   2.71 (-3.21%)
PFE   26.17 (-0.65%)
PYPL   65.17 (-0.96%)
XOM   122.04 (+0.21%)
S&P 500   5,151.19 (-0.92%)
DOW   38,162.29 (-0.77%)
QQQ   440.35 (-1.13%)
AAPL   176.66 (+0.93%)
MSFT   423.89 (-0.94%)
META   516.81 (-1.21%)
GOOGL   158.50 (-0.57%)
AMZN   187.40 (-0.87%)
TSLA   172.43 (-1.24%)
NVDA   895.04 (-1.23%)
AMD   164.15 (-3.72%)
NIO   4.15 (-6.95%)
BABA   72.46 (-3.19%)
T   16.42 (+0.00%)
F   12.68 (-2.76%)
MU   123.64 (-3.04%)
GE   154.31 (-1.96%)
CGC   8.31 (+1.96%)
DIS   114.50 (-2.26%)
AMC   2.71 (-3.21%)
PFE   26.17 (-0.65%)
PYPL   65.17 (-0.96%)
XOM   122.04 (+0.21%)
NASDAQ:JANX

Janux Therapeutics (JANX) Stock Price, News & Analysis

$53.96
+3.96 (+7.92%)
(As of 11:33 AM ET)
Today's Range
$49.53
$54.76
50-Day Range
$7.93
$50.00
52-Week Range
$5.65
$58.69
Volume
541,044 shs
Average Volume
746,609 shs
Market Capitalization
$2.79 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.60

Janux Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
10.5% Upside
$59.60 Price Target
Short Interest
Bearish
11.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.31mentions of Janux Therapeutics in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.41) to ($1.64) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.72 out of 5 stars

Medical Sector

1891st out of 2,784 stocks

Pharmaceutical Preparations Industry

874th out of 1,296 stocks

JANX stock logo

About Janux Therapeutics Stock (NASDAQ:JANX)

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

JANX Stock Price History

JANX Stock News Headlines

Stocks See Continued Pressure as Bond Yields Climb
Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Janux Therapeutics Inc Ordinary Shares JANX
Forecasting The Future: 4 Analyst Projections For Janux Therapeutics
See More Headlines
Receive JANX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/08/2024
Today
4/12/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:JANX
Fax
N/A
Employees
64
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$59.60
High Stock Price Target
$100.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+14.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-58,290,000.00
Net Margins
-721.18%
Pretax Margin
-721.18%

Debt

Sales & Book Value

Annual Sales
$8.08 million
Book Value
$7.46 per share

Miscellaneous

Free Float
33,372,000
Market Cap
$2.68 billion
Optionable
Optionable
Beta
4.18
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. David Alan Campbell Ph.D. (Age 64)
    President, CEO & Director
    Comp: $852.5k
  • Mr. Byron Robinson J.D. (Age 59)
    Ph.D., Chief Strategy Officer
    Comp: $606.8k
  • Mr. Tighe M. Reardon C.F.A. (Age 47)
    CPA, Acting Chief Financial Officer
  • Mr. Charles M. Winter (Age 55)
    Chief Technical Officer
  • Dr. Tommy Diraimondo Ph.D.
    Chief Scientific Officer
  • Mr. James Pennington
    General Counsel
  • Ms. Brenda Van Vreeswyk
    Head of Human Resources
  • Mr. Andy Hollman Meyer (Age 40)
    Chief Business Officer

JANX Stock Analysis - Frequently Asked Questions

Should I buy or sell Janux Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Janux Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JANX shares.
View JANX analyst ratings
or view top-rated stocks.

What is Janux Therapeutics' stock price target for 2024?

6 brokers have issued 1 year target prices for Janux Therapeutics' shares. Their JANX share price targets range from $35.00 to $100.00. On average, they anticipate the company's stock price to reach $59.60 in the next twelve months. This suggests a possible upside of 10.5% from the stock's current price.
View analysts price targets for JANX
or view top-rated stocks among Wall Street analysts.

How have JANX shares performed in 2024?

Janux Therapeutics' stock was trading at $10.73 on January 1st, 2024. Since then, JANX shares have increased by 402.9% and is now trading at $53.96.
View the best growth stocks for 2024 here
.

Are investors shorting Janux Therapeutics?

Janux Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 3,750,000 shares, an increase of 20.6% from the March 15th total of 3,110,000 shares. Based on an average daily volume of 711,600 shares, the short-interest ratio is currently 5.3 days. Approximately 11.6% of the company's stock are sold short.
View Janux Therapeutics' Short Interest
.

When is Janux Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our JANX earnings forecast
.

How were Janux Therapeutics' earnings last quarter?

Janux Therapeutics, Inc. (NASDAQ:JANX) announced its quarterly earnings data on Friday, March, 8th. The company reported ($0.25) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.12. The company earned $2.46 million during the quarter, compared to analysts' expectations of $0.98 million. Janux Therapeutics had a negative trailing twelve-month return on equity of 17.88% and a negative net margin of 721.18%.

What ETFs hold Janux Therapeutics' stock?

ETFs with the largest weight of Janux Therapeutics (NASDAQ:JANX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Fidelity Disruptive Medicine ETF (FMED).

When did Janux Therapeutics IPO?

Janux Therapeutics (JANX) raised $152 million in an initial public offering (IPO) on Friday, June 11th 2021. The company issued 9,500,000 shares at $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager.

How do I buy shares of Janux Therapeutics?

Shares of JANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:JANX) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners